LAWRENCEVILLE, N.J., Jan. 30, 2013 /P
Post# of 573
Posted On: 01/30/2013 4:06:47 PM
LAWRENCEVILLE, N.J., Jan. 30, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it will host a conference call and webcast at 8:00 a.m. Eastern Time on Thursday, January 31, 2013 to present the top-line results from its pivotal Phase III HEAT Study with ThermoDox in combination with radiofrequency ablation (RFA) in patients with intermediate hepatocellular carcinoma (HCC) versus those patients receiving RFA alone.
(0)
(0)Imunon, Inc. (IMNN) Stock Research Links
Scroll down for more posts ▼